These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 4050649)
1. The clinical electrophysiology of intravenous indecainide. Horowitz LN; Spielman SR; Webb CR; Morganroth J; Greenspan AM Am Heart J; 1985 Oct; 110(4):784-8. PubMed ID: 4050649 [TBL] [Abstract][Full Text] [Related]
2. Ethmozin. II. Effects of intravenous drug administration on atrioventricular nodal reentrant tachycardia. Chazov EI; Rosenshtraukh LV; Shugushev KK Am Heart J; 1984 Sep; 108(3 Pt 1):483-9. PubMed ID: 6382989 [TBL] [Abstract][Full Text] [Related]
3. Electrophysiology and antiarrhythmic efficacy of intravenous pirmenol in patients with sustained ventricular tachyarrhythmias. Liem LB; Clay DA; Franz MR; Swerdlow CD Am Heart J; 1987 Jun; 113(6):1390-6. PubMed ID: 3591608 [TBL] [Abstract][Full Text] [Related]
4. Ethmozine: electrophysiology, hemodynamics, and antiarrhythmic efficacy in patients with life-threatening ventricular arrhythmias. Dorian P; Echt DS; Mead RH; Lee JT; Lebsack CS; Winkle RA Am Heart J; 1986 Aug; 112(2):327-33. PubMed ID: 3526852 [TBL] [Abstract][Full Text] [Related]
5. Antiarrhythmic effects of indecainide in a drug-resistant population with ventricular tachycardia at programmed electrical stimulation. Miura DS; Wynn J; Keefe D; Laux B; Somberg JC Am Heart J; 1987 Jan; 113(1):65-9. PubMed ID: 3799443 [TBL] [Abstract][Full Text] [Related]
6. Antiarrhythmic effects of oral indecainide in patients with ventricular tachyarrhythmias. Macina G; Turitto G; Stavens C; Fontaine J; Hariman R; Ursell S; el-Sherif N Clin Cardiol; 1987 Jun; 10(6):357-61. PubMed ID: 3594958 [TBL] [Abstract][Full Text] [Related]
7. Electrophysiologic effects of cibenzoline in humans related to dose and plasma concentration. Touboul P; Atallah G; Kirkorian G; de Zuloaga C; Dufour A; Aymard MF; Lavaud P; Moleur P Am Heart J; 1986 Aug; 112(2):333-9. PubMed ID: 3526853 [TBL] [Abstract][Full Text] [Related]
8. Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia. Shen EN; Sung RJ; Morady F; Schwartz AB; Scheinman MM; DiCarlo L; Shapiro W J Am Coll Cardiol; 1984 May; 3(5):1291-7. PubMed ID: 6707382 [TBL] [Abstract][Full Text] [Related]
9. Antiarrhythmic and hemodynamic evaluation of indecainide and procainamide in nonsustained ventricular tachycardia. Pratt CM; Francis MJ; Seals AA; Zoghbi W; Young JB Am J Cardiol; 1990 Jul; 66(1):68-74. PubMed ID: 2193498 [TBL] [Abstract][Full Text] [Related]
10. Electrophysiologic effects of ethmozin in patients with ventricular tachycardia. Mann DE; Luck JC; Herre JM; Magro SA; Yepsen SC; Griffin JC; Pratt CM; Wyndham CR Am Heart J; 1984 Apr; 107(4):674-9. PubMed ID: 6367405 [TBL] [Abstract][Full Text] [Related]
11. Chronic effects of amiodarone in patients with refractory ventricular tachycardia. Saksena S; Rothbart ST; Cappello G Int J Cardiol; 1983 Jun; 3(3):339-52. PubMed ID: 6347914 [TBL] [Abstract][Full Text] [Related]
12. Electrocardiographic and electrophysiologic effects of pirmenol in ventricular tachycardia. Estes NA; Gold R; Cameron J; Haffajee C; Marshall M; Mack K; Salem DN Am J Cardiol; 1987 Jun; 59(16):20H-26H. PubMed ID: 3591711 [TBL] [Abstract][Full Text] [Related]
13. Sustained symptomatic sinus node reentrant tachycardia: incidence, clinical significance, electrophysiologic observations and the effects of antiarrhythmic agents. Gomes JA; Hariman RJ; Kang PS; Chowdry IH J Am Coll Cardiol; 1985 Jan; 5(1):45-57. PubMed ID: 3964808 [TBL] [Abstract][Full Text] [Related]
14. Ethmozin. I. Effects of intravenous drug administration on paroxysmal supraventricular tachycardia in the ventricular preexcitation syndrome. Chazov EI; Shugushev KK; Rosenshtraukh LV Am Heart J; 1984 Sep; 108(3 Pt 1):475-82. PubMed ID: 6382988 [TBL] [Abstract][Full Text] [Related]
15. [Cibenzoline: electrophysiologic effects of a new class I anti-arrhythmia agents in supraventricular tachycardia]. Pfitzner P; Manz M; Schütz R; Lüderitz B Z Kardiol; 1989 Oct; 78(10):654-60. PubMed ID: 2686252 [TBL] [Abstract][Full Text] [Related]
16. [Effect of a new class I anti-arrhythmia agent cibenzoline in patients with therapy refractory, sustained ventricular tachycardias]. Kühlkamp V; Ickrath O; Haasis R; Seipel L Z Kardiol; 1988 Sep; 77(9):595-9. PubMed ID: 3195178 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of nadolol alone or in combination with a type IA antiarrhythmic drug in sustained ventricular tachycardia: a prospective study. Munsif AN; Saksena S Pacing Clin Electrophysiol; 1989 Nov; 12(11):1816-26. PubMed ID: 2478982 [TBL] [Abstract][Full Text] [Related]
18. Effect of indecainide in patients with left ventricular dysfunction. Giardina EV; Saroff AL; Schneider M Clin Pharmacol Ther; 1990 Nov; 48(5):582-9. PubMed ID: 2225716 [TBL] [Abstract][Full Text] [Related]
19. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation. Roden DM; Lee JT; Woosley RL; Echt DS Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262 [TBL] [Abstract][Full Text] [Related]
20. Indecainide: effects on arrhythmias, electrophysiology, and cardiovascular dynamics. Holland DR; Lacefield WB; Gonzales CR; Johnston SR; Turk JA J Cardiovasc Pharmacol; 1989 Sep; 14(3):454-61. PubMed ID: 2476626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]